Development of Curcumin loaded Nanostructured Lipid Carriers: Preparation, Characterization and In-vitro Evaluation of Anti-cancer Activity Against A-549 Human Lung Cancer Cell Line
Journal of Cancer and Tumor International,
Aims: The present study was aimed at preparing stable lyophilized curcumin loaded nanostructured lipid carriers (NLCs). The optimized lyophilized curcumin loaded NLCs were characterized and evaluated for various quality control parameters.
Methodology: The optimized curcumin loaded NLCs were prepared by modified hot emulsification using compritol 888 ATO (CMPR), capmul MCM C8 EP (CAP) as solid and liquid lipids respectively. The combination of tween 80 (T80) and solutol HS 15 (SHS) were used as an emulsifier. The NLCs dispersion was lyophilized into powder form to improve the thermodynamic stability of the formulation. The lyophilized curcumin loaded NLCs were evaluated for particle size, size distribution, zeta potential, entrapment efficiency (EE), drug loading, assay, in-vitro drug release, crystallinity, thermal behavior and surface morphology studies.
Results: The optimized lyophilized curcumin loaded NLCs have a mean particle size of 332.88 ± 5.9 nm with a size distribution of 0.350 ± 0.007, a zeta potential of 0.098 ± 0.019 mV with high entrapment of 97.64 ± 1.59% and drug loading of 2.50 ± 0.16%. The X-ray diffraction and endothermic peaks confirmed the maximum encapsulation of curcumin in lipid matrices. The particles were spherical with smooth surface morphology. In-vitro release studies showed sustained release for up to 24 h. The cytotoxicity against human lung cancer line A-549 for curcumin loaded NLCs was confirmed with positive control adriamycin (ADR).
Conclusion: Curcumin loaded NLCs prepared had a nanosize particle distribution with maximum entrapment efficiency. Dispersion stability was increased by the lyophilization process. The solid lyophilized powder is reconstituted for oral delivery.
- nanostructured lipid carrier
- anti-cancer activity.
How to Cite
Allegra A, Innao V, Russo S, Gerace D, Alonci A, Musolino C. Anticancer activity of curcumin and its analogues: Preclinical and clinical studies. Cancer Invest 2017;35(1):1-22.
Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules 2015;20(2):2728-69.
Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta 2008;1780(4):673-9.
Syng-Ai C, Kumari AL, Khar A. Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2. Mol Cancer Ther. 2004;3(9):1101-8. PMID: 15367704.
Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? AAPS J. 2009;11(3):495-510.
Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-6.
Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007;595:453-70.
Liang S, Ji HF. The pharmacology of curcumin: is it the degradation products?. Trends Mol Med 2012;18(3):138-43.
Wang F, Ye X, Zhai D, Dai W, Wu Y, Chen J, et al. Curcumin-loaded nanostructured lipid carrier induced apoptosis in human HepG2 cells through activation of the DR5/caspase-mediated extrinsic apoptosis pathway. Acta Pharm. 2020;70(2):227-37.
Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv. 2016;23(4):1326-34.
Chanburee S, Tiyaboonchai W. Enhanced intestinal absorption of curcumin in Caco-2 cell monolayer using mucoadhesive nanostructured lipid carriers. J Biomed Mater Res B Appl Biomater. 2018:106(2):734-41.
Chen Y, Pan L, Jiang M, Li D, Jin L. Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and In vivo. Drug Deliv. 2016;23(4):1383-92.
Kamel AE, Fadel M, Louis D. Curcumin-loaded nanostructured lipid carriers prepared using Peceol™ and olive oil in photodynamic therapy: Development and application in breast cancer cell line. Int J Nanomedicine. 2019;14:5073-85.
Rabima, Oktamauri A. Characterisation and cytotoxicity assay of curcumin nanostructured lipid carrier on HeLa cells. Earth Environ Sci. 2021;667:1-8.
Wang F, Chen J, Dai W, He Z, Zhai D, Chen W. Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers. Acta Pharm. 2017;67(3):357-71.
Rapalli VK, Kaul V, Waghule T, Gorantla S, Sharma S, Roy A, et al. Curcumin loaded nanostructured lipid carriers for enhanced skin retained topical delivery: Optimization, scale-up, in-vitro characterization and assessment of ex-vivo skin deposition. Eur J Pharm Sci 2020;152:1-56.
Arora R, Katiyar SS, Kushwah V, Jain S. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opin. Drug Deliv. 2017;14(2):165-77.
Jain S, Cherukupalli SK, Mahmood A, Gotantla S, Rapalli VK, Dubey SK, et al. Emerging nanoparticulate systems: Preparation techniques and stimuli responsive release characteristics. J Appl Pharm Sci. 2019;9(08):130-43.
Sonawane R, Harde H, Katariya M, Agrawal S, Jain S. Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert Opin Drug Deliv 2014;11(12):1833-47.
Panigrahi S, Hirlekar R. A new stability-indicating RP-HPLC method for determination of curcumin: an application to nanoparticulate formulation. Int J Pharm Pharma Sci 2016;8(12):149-55.
Behbahani ES, Ghaedi M, Abbaspour M, Rostamizadeh K, Dashtian K. Curcumin loaded nanostructured lipid carriers: In vitro digestion and release studies. Polyhedron. 2019;164:113-22.
Padhye SG, Nagarsenker MS. Simvastatin solid lipid nanoparticles for oral delivery: Formulation development and In vivo evaluation. Indian J Pharm Sci. 2013:75(5):591-8.
Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1997;48(2):223-36.
Aihua S, Xiaoshu Z, Yanting L, Xinjuan M, Fei H. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci. 1993;82(10):979-87.
Maryam BZ, Akram P. Effect of surfactant concentration on the particle size, stability and potential zeta of beta carotene nano lipid carrier. Int J Curr Microbiol App Sci. 2015;4(9):924-32.
Helgason T, Awad TS, Kristbergsson K, McClements DJ, Weiss J. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci. 2009;334(1):75–81.
Kovacevic A, Savic S, Vuletaa G, Müller RH, Keck CM. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, physical stability and particle matrix structure. Int J Pharm. 2011;406(1):163-72.
Wolfgang M, Karsten M. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2):165-96.
Silva AC, González-Mira E, García ML, Egea MA, Fonseca J, Silva R, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces 2011;86(1):158-65.
Amis TM, Renukuntla J, Bolla PK, Clark BA. Selection of cryoprotectant in lyophilization of progesterone-loaded stearic acid solid lipid nanoparticles. Pharmaceutics. 2020;12(9):1-15.
Hu FX, Neoh KG, Kang ET. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials. 2006; 27(33):5725-33.
Ghorpade K, Shinde S. Design and development of curcumin loaded nanostructured lipid carriers for solubility enhancement. Int J Curr Res. 2019; 11(01):20-6.
Abstract View: 185 times
PDF Download: 58 times